Dashboard
Manage Tickers

STSASatsuma Pharmaceuticals, Inc.

Nasdaq satsumarx.com


$ 1.09 $ -0.01 (-0.9 %)    

Wednesday, 07-Jun-2023 15:55:14 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.95 $ 3.06 (0.68 %)
DIA $ 398.69 $ 0.81 (0.2 %)
SPY $ 528.58 $ 2.66 (0.51 %)
TLT $ 92.20 $ 0.36 (0.39 %)
GLD $ 221.00 $ 1.76 (0.8 %)
$ 1.1
$ 1.11
$ 0.00 x 0
$ 0.00 x 0
$ 1.02 - $ 1.11
$ 0.59 - $ 8.08
1,829,701
na
36.47M
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-11-2023 03-31-2023 10-Q
2 03-28-2023 12-31-2022 10-K
3 11-03-2022 09-30-2022 10-Q
4 08-09-2022 06-30-2022 10-Q
5 05-10-2022 03-31-2022 10-Q
6 03-15-2022 12-31-2021 10-K
7 11-09-2021 09-30-2021 10-Q
8 08-10-2021 06-30-2021 10-Q
9 05-11-2021 03-31-2021 10-Q
10 03-25-2021 12-31-2020 10-K
11 11-10-2020 09-30-2020 10-Q
12 08-11-2020 06-30-2020 10-Q
13 05-12-2020 03-31-2020 10-Q
14 03-10-2020 12-31-2019 10-K
15 11-12-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

satsuma-pharmaceuticals-and-2-other-penny-stocks-insiders-are-aggressively-buying
Satsuma Pharmaceuticals And 2 Other Penny ...
06/09/2023 11:30:21

The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidenc...

satsuma-pharmaceuticals-announces-fda-acceptance-of-505b2-nda-for-sts101-a-novel-and-investigational-dihydroergotamine-nasal-powder-product-for-the-acute-treatment-of-migraine
Satsuma Pharmaceuticals Announces FDA Acce...
05/18/2023 20:03:21

January 2024 PDUFA date expected If approved, STS101 would become the only DHE product evaluated in a randomized, placebo-co...

satsuma-pharmaceuticals-said-on-may-1-received-letter-notifying-co-regained-compliance-with-nasdaq-listing-rule-5450a
Satsuma Pharmaceuticals Said On May 1, Rec...
05/03/2023 20:58:33

Core News & Articles
Benzinga's Top Ratings Upgrades, Downgrade...
04/18/2023 15:00:47

hc-wainwright--co-downgrades-satsuma-pharma-to-neutral
HC Wainwright & Co. Downgrades Satsuma Pha...
04/18/2023 10:23:15

HC Wainwright & Co. analyst Oren Livnat downgrades Satsuma Pharma (NASDAQ:STSA) from Buy to Neutral.

crude-oil-down-2-state-street-shares-tumble-after-downbeat-results
Crude Oil Down 2%; State Street Shares Tum...
04/17/2023 18:39:46

U.S. stocks traded slightly lower toward the end of trading. The Dow traded down 0.07% to 33,862.05 while the NASDAQ fell 0.24...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
04/17/2023 17:31:26

why-satsuma-pharmaceuticals-shares-are-trading-higher-by-94-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Satsuma Pharmaceuticals Shares Are Tra...
04/17/2023 17:27:37

Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.

gold-drops-below-2000-charles-schwab-earnings-top-views
Gold Drops Below $2,000; Charles Schwab Ea...
04/17/2023 16:02:37

U.S. stocks traded mostly flat midway through trading, following the release of economic data. The Dow traded up 0.01% to 33,8...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
04/17/2023 13:06:18

why-marpai-shares-are-trading-lower-by-26-here-are-20-stocks-moving-premarket
Why Marpai Shares Are Trading Lower By 26%...
04/17/2023 12:15:10

Gainers CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) jumped 153% to $5.96 in pre-market trading after jumping 243% on Friday.

reported-on-sunday-april-16-snbl-to-acquire-all-outstanding-shares-of-satsuma-for-upfront-cash-consideration-of-091-per-share-satsuma-stockholders-to-also-receive-non-tradeable-contingent-value-right-of-up-to-577-per-share
Reported On Sunday April 16, SNBL To Acqui...
04/17/2023 05:47:56

Transaction delivers immediate value and liquidity to Satsuma stockholders   SNBL to acquire all outstanding shares of Satsuma...

mizuho-reiterates-neutral-on-satsuma-pharma-maintains-2-price-target
Mizuho Reiterates Neutral on Satsuma Pharm...
03/30/2023 12:26:38

Mizuho analyst Uy Ear reiterates Satsuma Pharma (NASDAQ:STSA) with a Neutral and maintains $2 price target.

hc-wainwright--co-reiterates-buy-on-satsuma-pharma-maintains-3-price-target
HC Wainwright & Co. Reiterates Buy on Sats...
03/30/2023 10:26:48

HC Wainwright & Co. analyst Oren Livnat reiterates Satsuma Pharma (NASDAQ:STSA) with a Buy and maintains $3 price target.

satsuma-pharmaceuticals-q4-eps-070-misses-036-estimate
Satsuma Pharmaceuticals Q4 EPS $(0.70) Mis...
03/28/2023 20:23:42

Satsuma Pharmaceuticals (NASDAQ:STSA) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimat...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
03/07/2023 21:31:15

why-universal-electronics-shares-are-trading-lower-by-30-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Universal Electronics Shares Are Tradi...
02/17/2023 17:26:01

Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology tar...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
12/26/2022 13:07:31

despite-trial-failure-satsuma-pharma-says-its-migraine-candidate-has-potential-for-approval
Despite Trial Failure, Satsuma Pharma Says...
12/20/2022 17:46:58

Satsuma Pharmaceuticals Inc (NASDAQ: STSA) provided an update on its STS101 development program and corporate update.

satsuma-pharmaceuticals-says-analysis-of-results-from-recently-completed-summit-phase-3-efficacy-trial-of-sts101-for-the-acute-treatment-of-migraine-shows-differentiating-robust-sustained-antimigraine-effects-on-clinically-important-secondary-endpoints
Satsuma Pharmaceuticals Says Analysis Of R...
12/20/2022 14:23:30

Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update Further analysis of results from recently-c...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION